People: Dendreon Corp (DNDN.O)
DNDN.O on Nasdaq
4.10USD
17 Jun 2013
4.10USD
17 Jun 2013
Price Change (% chg)
$0.05 (+1.23%)
$0.05 (+1.23%)
Prev Close
$4.05
$4.05
Open
$4.10
$4.10
Day's High
$4.10
$4.10
Day's Low
$3.97
$3.97
Volume
2,372,672
2,372,672
Avg. Vol
4,112,095
4,112,095
52-wk High
$7.94
$7.94
52-wk Low
$3.69
$3.69
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
John Johnson |
55 | 2012 | Chairman of the Board, President, Chief Executive Officer |
Gregory Schiffman |
56 | 2010 | Chief Financial Officer, Executive Vice President, Treasurer |
Christine Cvijic |
35 | 2012 | Executive Vice President - Corporate Development, General Counsel, Secretary |
Gregory Mayes |
44 | 2013 | Executive Vice President - Human Resources |
Joseph DePinto |
45 | 2012 | Executive Vice President - Commercial Operations |
Mark Frohlich |
51 | 2011 | Executive Vice President - Research and Development and Chief Medical Officer |
William Monteith |
55 | 2013 | Executive Vice President - Technical Operations |
Lindsay Rocco |
34 | 2012 | Executive Vice President - Corporate Communications |
Douglas Watson |
68 | 2012 | Lead Independent Director |
David Urdal |
63 | 2011 | Director |
Susan Bayh |
53 | 2003 | Independent Director |
Bogdan Dziurzynski |
64 | 2001 | Independent Director |
Dennis Fenton |
61 | 2011 | Independent Director |
Pedro Granadillo |
65 | 2009 | Independent Director |
David Stump |
63 | 2010 | Independent Director |
Biographies
| Name | Description |
|---|---|
John Johnson |
Mr. John H. Johnson is Chairman of the Board, President, Chief Executive Officer of Dendreon Corp. He has served as a member of the Board of Directors since August 2011, and was named Chair in July 2013. He has also served as President and Chief Executive Officer since January 2012. Mr. Johnson previously served as the Chief Executive Officer and a director of Savient Pharmaceuticals, Inc., a pharmaceutical company, from January 2011 until January 2012, and prior to that time, served as Senior Vice President and President of Eli Lilly and Company’s Oncology unit from November 2009 until January 2011. He was also Chief Executive Officer of ImClone Systems Incorporated (“ImClone”), which develops targeted biologic cancer treatments, from August 2007 until November 2009, and served on ImClone’s Board of Directors until it was acquired by Eli Lilly in November 2008. Prior to joining ImClone, Mr. Johnson served as Company Group Chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals unit from 2005 until August 2007, President of its Ortho Biotech Products LP and Ortho Biotech Canada unit from 2003 until 2005, and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 until 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corporation and Pfizer, Inc. Mr. Johnson currently serves as Chairman of the Board of Directors of Tranzyme, Inc., a clinical stage biopharmaceutical company, and as a director of Cempra, Inc., a clinical stage pharmaceutical company. He earned his bachelor’s degree from the East Stroudsburg University of Pennsylvania. |
Gregory Schiffman |
Mr. Gregory T. Schiffman is Chief Financial Officer, Executive Vice President, Treasurer of Dendreon Corporation, since December 2010. Mr. Schiffman joined the Company in December 2006 as Senior Vice President, Chief Financial Officer and Treasurer. Prior to that time, Mr. Schiffman was the Executive Vice President and Chief Financial Officer of Affymetrix, Inc., a manufacturer of genetic analysis products. He served as Affymetrix’s Vice President of Finance from March 2001 and was appointed Vice President and Chief Financial Officer in August 2001. At Affymetrix, Mr. Schiffman was promoted to Senior Vice President in October 2002 and to Executive Vice President in February 2005. Prior to joining Affymetrix, Mr. Schiffman was Vice President, Controller of Applied Biosystems, Inc. from October 1998. From 1987 through 1998, Mr. Schiffman held various managerial and financial positions at Hewlett Packard Company. Mr. Schiffman served as a director of Vnus Technologies, Inc., a medical device company from April 2006 until July 2009, Xenogen Corporation, a life sciences tools company from January 2005 until August 2006, and Impac Software Medical Systems, Inc., an information systems company making products for managing radiation and medical oncology practices from February 2003 until April 2005. Mr. Schiffman received a Bachelor of Science from De Paul University and a Master of Business Administration from the Kellogg School at Northwestern University. |
Christine Cvijic |
Ms. Christine Mikail Cvijic has been appointed as Executive Vice President - Corporate Development, General Counsel, Secretary of Dendreon Corp., effective February 28, 2012. Ms. Mikail previously served as Senior Vice President, Corporate Strategy and Corporate Development at Savient Pharmaceuticals, Inc., a specialty bio-pharmaceutical company, from February 2011 until February 2012. From March 2008 until February 2011, Ms. Mikail held several positions at both ImClone, a wholly-owned subsidiary of Eli Lilly and Company, and Eli Lilly and Company, and served as Vice President, General Counsel and Secretary of ImClone prior to her departure. Prior to that time, Ms. Mikail worked at the law firms of Reed Smith LLP from August 2005 until March 2008, Lowenstein Sandler PC from 2004 until 2005, and WilmerHale during 2001 and from 2002 until 2004. She earned her Bachelor of Arts from Rutgers University and J.D. from Fordham University School of Law. |
Gregory Mayes |
Mr. Gregory T. Mayes is Executive Vice President - Human Resources of Dendreon Corporation, since January 2013. Mr. Mayes joined Dendreon from Unigene Laboratories Inc. (“Unigene”), where he most recently served as the President and General Counsel and as a member of the Board of Directors. Mr. Mayes worked at Unigene from October 2010 to December 2012. Mr. Mayes served on the Unigene Board of Directors from September 2012 to December 2012. From 2005 to October 2010, Mr. Mayes held several positions of increasing responsibility at ImClone, a wholly-owned subsidiary of Eli Lilly and Company, and served as Vice President, General Counsel and Chief Compliance Officer prior to his departure. Prior to ImClone, Mr. Mayes was Senior Counsel at AstraZeneca Pharmaceuticals, LP, from 2001 to 2005. Earlier, Mr. Mayes worked in private practice at Morgan Lewis LLP, national law firm and earned his B.S. degree from Syracuse University, cum laude, and his J.D. degree, magna cum laude, from the Temple University School of Law, where he was the Articles Editor on the Temple Law Review. |
Joseph DePinto |
Mr. Joseph I. DePinto has been appointed as Executive Vice President - Commercial Operations of Dendreon Corp., effective February 28, 2012. Previously, Mr. DePinto served as Vice President Product Champion at ImClone, a wholly-owned subsidiary of Eli Lilly and Company, for IMC-11F8 (necitumumab) from July 2010 until February 2012. Prior to that time, Mr. DePinto served as Vice President of U.S. Sales and Marketing at Abraxis Bioscience, an oncology biotech company and now a wholly-owned subsidiary of Celgene Corporation, from October 2009 until March 2010. Mr. DePinto also served as Vice President, Commercial Operations for ImClone from July 2008 until October 2009, and Global Marketing Leader of Oncology Therapeutics at Johnson & Johnson Pharmaceutical Services, Inc. from January 2006 until July 2008. Mr. DePinto has spent 20 years of his career working in oncology at both pharmaceutical and biotech companies. He earned his Bachelor of Science in Marketing and his Master of Business Administration in Pharmaceutical Chemical Studies from Fairleigh Dickinson University. |
Mark Frohlich |
Dr. Mark W. Frohlich, M.D., is Executive Vice President - Research and Development, Chief Medical Officer of Dendreon Corporation, since March 2011. Prior to that time served as Executive Vice President for Clinical Affairs and Chief Medical Officer from December 2010 to March 2011. Previously, Dr. Frohlich served as Senior Vice President for Clinical Affairs and Chief Medical Officer from January 2008 to December 2010. Dr. Frohlich also served as Vice President of Clinical Affairs from April 2006, and from August 2005, served as Senior Medical Director. Prior to joining Dendreon, Dr. Frohlich was Vice President and Medical Director at Xcyte Therapies, Inc., a biotechnology company, from October 2001 to July 2005. From 1998 to 2001, Dr. Frohlich was a member of the faculty of the University of California at San Francisco where he served as an assistant professor in the Division of Hematology/Oncology. Dr. Frohlich received a Bachelor of Science in electrical engineering and economics from Yale University and an M.D. from Harvard Medical School. |
William Monteith |
Mr. William Monteith is Executive Vice President - Technical Operations of Dendreon Corporation, since January 2013. Previously he served as Vice President, Technical Operations Strategy from October 2012 to December 2012 and Vice President and General Manager of the Morris Plains, New Jersey manufacturing facility from May 2009 to October 2012. Prior to joining Dendreon, Mr. Monteith served as Vice President, Technical Operations at Sandoz Corporation, a division of Novartis, from June 2008 to May 2009. From July 2004 to June 2008, Mr. Monteith was Vice President, Operations at Shire Pharmaceuticals. Prior to July 2004, Mr. Monteith spent 22 years with Wyeth Pharmaceuticals in various roles with increasing responsibilities in the areas of manufacturing, technical support/validation, and quality operations. Throughout his 30-year career, Mr. Monteith has garnered experience in technical operations, quality assurance, and manufacturing operations. Mr. Monteith holds a Bachelor of Science degree in chemistry/pre-medical studies from Saint Lawrence University, Canton, New York. |
Lindsay Rocco |
Ms. Lindsay Rocco has been appointed as Executive Vice President - Corporate Communications of Dendreon Corp., effective November 14, 2012. Most recently, Ms. Rocco served as Senior Vice President and a member of the leadership team at Rx Mosaic Health from February 2010 to November 2012. Prior to that, Ms. Rocco served as a Director, Public Affairs at Roche-Genentech from June 2008 to January 2010. Throughout her career, Ms. Rocco has held senior-level positions with several healthcare public relations agencies within global holding companies, including the Omnicom Group and Publicis, and with MCS Healthcare Public Relations, an independent agency. She currently serves on the Board of Governors for the New York Chapter of the Arthritis Foundation. Ms. Rocco holds a Bachelor of Business Administration in Marketing from the Joseph A. Sellinger School of Business Administration and Management at Loyola University in Maryland. |
Douglas Watson |
Mr. Douglas G. Watson has been appointed as Lead Independent Director of Dendreon Corporation, effective January 31, 2012. Mr. Watson has served as a member of the Board of Directors since February 2000. Mr. Watson is Chief Executive Officer of Pittencrieff Glen Associates, a consulting firm that he founded in July 1999. From January 1997 to May 1999, Mr. Watson served as President and Chief Executive Officer of Novartis Corporation, the U.S. subsidiary of Novartis AG. From April 1996 to December 1996, Mr. Watson served as President and Chief Executive Officer of Ciba-Geigy Corporation, which merged into Novartis Corporation in December 1996. Mr. Watson’s career spanned 33 years with Novartis, having joined Geigy (UK) Ltd. in 1966. Mr. Watson also currently serves as Chairman of OraSure Technologies, Inc., a medical diagnostics company, and as a director of Delcath Systems, Inc., a specialty pharmaceutical and medical device company. Mr. Watson previously served on the Board of Directors of BioMimetic Therapeutics, Inc., a biotechnology company, from 1999 to March 2013, Genta Incorporated, a biopharmaceutical company, from 2002 to January 2011, Javelin Pharmaceuticals, Inc., a pharmaceutical company, from 2004 to 2010, and Engelhard Corporation, a surface and materials science company, from 1991 to 2006. Mr. Watson received an M.A. in Pure Mathematics from Churchill College, Cambridge University and holds an ACMA qualification as an Associate of the Chartered Institute of Management Accountants. |
David Urdal |
Dr. David L. Urdal, Ph.D., is Director of Dendreon Corporation, since July 1995. Until his retirement in December 2011, he served as Executive Vice President and Chief Scientific Officer since December 2010, and previously served as Chief Scientific Officer and director since joining the Company in July 1995. He also served as Vice Chair of the Company’s Board of Directors from 1995 to June 2004, as Executive Vice President from January 1999 through December 2000, as the Company’s President from January 2001 to December 2003, and as Senior Vice President since June 2004. From 1982 until July 1995, Dr. Urdal held various positions with Immunex Corporation, a biotechnology company, including President of Immunex Manufacturing Corporation, Vice President and Director of Development, and head of the departments of biochemistry and membrane biochemistry. Dr. Urdal serves as a director of VLST, a biotechnology company and previously served as a director of ORE Pharmaceuticals, Inc., a pharmaceutical drug repositioning and development company, from 2007 until 2010. Dr. Urdal received a B.S. in zoology, a M.S. in Public Health and a Ph.D. in Biochemical Oncology from the University of Washington. |
Susan Bayh |
Ms. Susan B. Bayh is Independent Director of Dendreon Corp. Prior to that, she served as a director of Corvas from June 2000 to July 2003. Ms. Bayh, retired since 2004, was a Distinguished Visiting Professor at the College of Business Administration at Butler University in Indianapolis, Indiana from 1994 to 2004. From 1994 to 2001, she was a Commissioner for the International Commission between the United States and Canada, overseeing compliance with environmental and water level treaties for the United States-Canada border. From 1989 to 1994, Ms. Bayh served as an attorney in the Pharmaceutical Division of Eli Lilly and Company. She currently serves on the Boards of Directors of Wellpoint, Inc., a health benefits company, Curis, Inc., a therapeutic drug development company, and Emmis Communications, a diversified media company, and previously served on the Board of Directors of Dyax Corp., a biotechnology company, from 2003 to March 2012 and MDRNA, Inc. (formerly Nastech Pharmaceutical Company Inc.), a biotechnology company, from 2006 to 2009. Ms. Bayh received a B.S. from the University of California, Berkeley and her J.D. from the University of Southern California Law School. |
Bogdan Dziurzynski |
Dr. Bogdan Dziurzynski is Independent Director of Dendreon Corporation, since May 2001. Since 2001, Dr. Dziurzynski has been a consultant in strategic regulatory management to the biotechnology industry. Dr. Dziurzynski currently serves on the Board of Directors of Anthera Pharmaceuticals Inc. and previously served on the Board of Directors of the Biologics Consulting Group and Allostera Pharma Inc. Dr. Dziurzynski is a fellow and past Chairman of the Board of the Regulatory Affairs Professional Society. From 1994 to 2001, Dr. Dziurzynski was the Senior Vice President of Regulatory Affairs and Quality Assurance for MedImmune, Inc., a biotechnology company. From 1988 to 1994, Dr. Dziurzynski was Vice President of Regulatory Affairs and Quality Assurance for Immunex Corporation, a biotechnology company. Dr. Dziurzynski has a B.A. in Psychology from Rutgers University, an M.B.A. from Seattle University and a Doctorate in Public Administration from the University of Southern California. |
Dennis Fenton |
Dr. Dennis M. Fenton, Ph.D., has been appointed as Independent Director of Dendreon Corporation, effective November 8, 2011. Dr. Fenton, who retired in 2008, previously held numerous positions from 1982 to 2008 at Amgen, Inc., a biotechnology company, including executive roles in process development, manufacturing, sales and marketing and research and development. From 2000 until 2008, Dr. Fenton was Executive Vice President responsible for worldwide operations, manufacturing, process development and quality. From 1995 until 2000, Dr. Fenton was Senior Vice President of Operations, and from 1992 until 1995, he was Senior Vice President of Sales, Marketing and Process Development. Prior to his time at Amgen, Inc., Dr. Fenton served as Senior Research Scientist at Pfizer, Inc., and previously was a research associate and graduate student at Rutgers University. Dr. Fenton currently serves as a member of the Board of Directors at Hopspira Inc., a publicly traded biopharmaceutical company, XenoPort, Inc., a publicly traded biopharmaceutical company, Kythera Biopharmaceuticals, Inc., a publicly traded biopharmaceutical company, Genelux Corporation, a biomedical company, and Napo Pharmaceuticals, Inc., a pharmaceutical company. He received his B.S. in Biology from Manhattan College and his Ph.D. in Microbiology from Rutgers University. |
Pedro Granadillo |
Mr. Pedro P. Granadillo is Independent Director of Dendreon Corporation, since October 2009. Mr. Granadillo, now retired since 2004, was most recently Senior Vice President of Global Manufacturing, Quality and Human Resources until 2004 as well as a member of the executive committee at Eli Lilly and Company, a pharmaceutical company. Mr. Granadillo worked at Eli Lilly and Company for over thirty years from 1970 to 2004, serving in roles such as Vice President of Human Resources, Vice President of Pharmaceutical Manufacturing, Executive Director, Production Operations and Director of Manufacturing Strategy Development. As the company’s top executive for both manufacturing and human resources, Mr. Granadillo was responsible for the overall management of an network of pharmaceutical manufacturing facilities and for policies affecting the company’s global workforce of more than 43,000 employees. He currently serves on the Board of Directors of Haemonetics Corporation, a blood processing company, NPS Pharmaceuticals, Inc., a biopharmaceutical company and Nile Therapeutics, Inc., a biopharmaceutical company, and served on the Board of Directors of Noven Pharmaceuticals, Inc., a pharmaceutical company, from 2004 to 2009, and First Indiana Bank, a banking company, from 2002 to 2007. Mr. Granadillo received a B.S. in industrial engineering from Purdue University. |
David Stump |
Dr. David C. Stump, M.D. is Independent Director of Dendreon Corporation, since June 2010. Dr. Stump was most recently at Human Genome Sciences, Inc. from November 1999 until December 2012. He served as Executive Vice President of Research and Development at Human Genome Sciences, Inc. from May 2007 to December 2012, Executive Vice President of Drug Development from December 2003 to May 2007, and Senior Vice President, Drug Development from November 1999 to December 2003. Prior to joining Human Genome Sciences, Inc., Dr. Stump held several positions at Genentech, Inc., including Vice President of Clinical Research, and was named a Genentech Fellow in 1996 for leadership of its cardiovascular drug development activities. Prior to Genentech, Dr. Stump served as Associate Professor of Medicine and Biochemistry at the University of Vermont. He is currently a member of the Board of Directors for Sunesis Pharmaceuticals, Inc., a pharmaceutical company, as well as of the Board of Trustees for Earlham College. Dr. Stump received his M.D. from Indiana University and his bachelor’s degree from Earlham College. Dr. Stump completed his residency and fellowship training in internal medicine, hematology, and oncology at the University of Iowa and is board certified in all three areas. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
John Johnson |
11,177,000 |
Gregory Schiffman |
1,697,020 |
Christine Cvijic |
2,351,400 |
Gregory Mayes |
-- |
Joseph DePinto |
-- |
Mark Frohlich |
3,057,300 |
William Monteith |
-- |
Lindsay Rocco |
-- |
Douglas Watson |
-- |
David Urdal |
1,589,610 |
Susan Bayh |
-- |
Bogdan Dziurzynski |
-- |
Dennis Fenton |
-- |
Pedro Granadillo |
-- |
David Stump |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
John Johnson |
0 | 0 |
Gregory Schiffman |
40,708 | 1,027,060 |
Christine Cvijic |
0 | 0 |
Gregory Mayes |
0 | 0 |
Joseph DePinto |
0 | 0 |
Mark Frohlich |
18,510 | 274,501 |
William Monteith |
0 | 0 |
Lindsay Rocco |
0 | 0 |
Douglas Watson |
0 | 0 |
David Urdal |
720,467 | 4,433,710 |
Susan Bayh |
0 | 0 |
Bogdan Dziurzynski |
0 | 0 |
Dennis Fenton |
0 | 0 |
Pedro Granadillo |
0 | 0 |
David Stump |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
DEPINTO JOSEPH I |
958 | $3.90 |
CVIJIC CHRISTINE MIKAIL |
1,380 | $3.90 |
MONTEITH WILLIAM J |
133 | $4.57 |
FROHLICH MARK W |
384 | $4.57 |
SCHIFFMAN GREGORY T |
320 | $4.57 |
COX GREGORY ROBERT |
128 | $4.57 |
MONTEITH WILLIAM J |
204 | $4.57 |
FROHLICH MARK W |
359 | $4.57 |
COX GREGORY ROBERT |
162 | $4.57 |
SCHIFFMAN GREGORY T |
359 | $4.57 |
MONTEITH WILLIAM J |
1,073 | $4.55 |
SCHIFFMAN GREGORY T |
2,563 | $4.70 |
FROHLICH MARK W |
2,563 | $4.70 |
COX GREGORY ROBERT |
888 | $4.70 |
DEPINTO JOSEPH I |
3,793 | $5.91 |
CVIJIC CHRISTINE MIKAIL |
5,520 | $5.91 |
RANIERI RICHARD J |
414 | $5.88 |
MAYES GREGORY T |
150,000 | $0.00 |
RANIERI RICHARD J |
166 | $5.88 |
FROHLICH MARK W |
372 | $6.31 |
SCHIFFMAN GREGORY T |
310 | $6.31 |
MONTEITH WILLIAM J |
156 | $6.31 |
COX GREGORY ROBERT |
125 | $6.31 |
FROHLICH MARK W |
348 | $6.31 |
MONTEITH WILLIAM J |
236 | $6.31 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
